Medicare AdvantageCoverageMedium impact
MA08.187, Nipocalimab-aahu (Imaavy)
Independence Blue Cross·Pharmacy, Internal Medicine·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
MA08.187 is a new Medicare Advantage policy effective January 1, 2026, establishing coverage guidelines for Nipocalimab-aahu (Imaavy), a monoclonal antibody therapeutic. This is a pharmacy policy that introduces new coverage requirements and billing procedures for this drug. Billing teams must implement coverage validation and prior authorization protocols per this new policy.
Action Required
By December 15, 2025: Billing and pharmacy teams must review the full MA08.187 policy at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=01&FilterField2=MPSiteActivityLogYear&FilterValue2=2026 to identify specific prior authorization requirements, medical necessity criteria, and covered indications for Nipocalimab-aahu (HCPCS J7171). Update billing system edits to enforce any prior authorization requirements before claims submission. Train pharmacy and billing staff on coverage criteria. Beginning January 1, 2026, all claims for J7171 must comply with the policy requirements or face denial. Verify patient eligibility on Medicare Advantage plans and obtain required authorizations before drug administration.